What is the coverage of tepotinib by domestic medical insurance? How are patients reimbursed?

Tepotinib is an oral targeted drug developed for non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations. It was developed by Merck KGaA of Germany. It is a highly selective MET tyrosine kinase inhibitor (TKI) that can effectively block the MET signaling pathway, thereby inhibiting tumor growth. Currently, tepotinib has been approved for marketing in many countries and approved in China for the treatment of patients with locally advanced or metastatic NSCLC carrying MET exon 14 skipping mutations.

For patients, drug accessibility is a crucial issue in treatment, and medical insurance reimbursement policies are directly related to whether patients can persist in taking drugs for a long time. Tepotinib has been launched in the country and has been successfully included in my country's medical insurance directory. This means that eligible patients can reduce their drug cost burden through medical insurance reimbursement. However, it should be noted that medical insurance reimbursement usually has strict indication restrictions and is only applicable to adult patients with locally advanced or metastatic NSCLC carrying MET exon 14 skipping mutations. The specific reimbursement ratio, deductible and personal contribution will vary depending on the medical insurance policies of different regions. Therefore, patients are recommended to consult the medical insurance department or pharmacy of the local hospital to obtain the latest reimbursement policy information.

In terms of the medical insurance reimbursement process, patients usually need to provide relevant medical certificates, such as genetic test reports, confirmed medical records, doctor's prescriptions, etc., to prove that they meet the indications covered by medical insurance. In some areas, registration or approval may be required before it can be formally included in the scope of medical insurance reimbursement. In addition, if the patient chooses to purchase medicines outside the hospital, it may also involve issues with designated pharmacies or pharmacies designated by medical insurance. Therefore, understanding the relevant policies in advance can complete the reimbursement process more smoothly.

Reference materials:https://www.tepotinib.com/